Prostate Cell News 10.47 December 13, 2019 | |
| |
TOP STORYIdentification of Therapeutic Vulnerabilities in Small Cell Neuroendocrine Prostate Cancer Scientists tested inhibitors to highly upregulated drug targets in a panel of prostate cancer cell lines and in vivo patient-derived xenograft models. [Clin Cancer Res] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Investigators conducted a focused shRNA screen of chromatin modifying enzymes previously shown to be involved in cellular differentiation. They found that altering the balance between histone methylation and demethylation impacted growth and proliferation. [Oncogene] Full Article In vitro results showed that titanate-nanotube-gold-nanoparticle-heterobifunctional-polymer-docetaxel had a substantial cytotoxic activity on human PC3 prostate adenocarcinoma cells, unlike initial nanohybrids without docetaxel. [Cancers] Abstract Researchers showed B55α reconstitution reduced phosphorylation of proteins essential for centrosomal maintenance, and induced centrosome collapse and chromosome segregation failure. [Oncogenesis] Abstract | Full Article Scientists investigated the aberrant activation of HGF/MET proto-oncogene receptor tyrosine kinase and Wnt/β-catenin cascades in prostate tumorigenesis by using a newly generated mouse model in which both murine Met transgene and stabilized β-catenin were conditionally co-expressed in prostatic epithelial cells. [J Biol Chem] Full Article Bone Secreted Factors Induce Cellular Quiescence in Prostate Cancer Cells The authors found that Calvarial-conditioned media treatment increased cellular quiescence in C4-2B4 prostate cancer cells. Mass spectrometry analysis of Calvarial-conditioned media identified 132 secreted factors. [Sci Rep] Full Article Cell fate regulator ASCL1/hASH1’s expression was markedly induced in androgen deprived LNCaP cells and prominent nuclear localisation accompanied acquisition of the neuroendocrine-like morphology and expression of neuroendocrine markers. [Sci Rep] Full Article The authors investigated the protein expression profile of stanniocalcin-1 in prostate cancer and benign prostatic hyperplasia samples and stanniocalcin-1 signaling during cell proliferation and cell death in vitro using cell lines. [Mol Cell Endocrinol] Abstract Researchers examined the role of heparan sulfate in prostate stem/progenitor cells self-renewal and prostate regeneration. Using an in vitro prostate sphere formation assay, they found that deletion of the glycosyltransferase exostosin 1 abolished heparan sulfate expression in prostate stem cells. [Glycobiology] Abstract A dual fluorescent biosensor plasmid was transfected in LNCaP cells to measure mitophagy. The DNA of LNCaP cells was extracted and performed with quantitative real-time PCR to detect mitochondrial DNA copy number. [Cancer Cell Int] Full Article Subscribe to one of our other 19 science newsletters such as Mammary Cell News & ESC & iPSC News. | |
| |
REVIEWSNoncanonical Wnt as a Prognostic Marker in Prostate Cancer: “You Can’t Always Get What You Wnt” Scientists review the literature with regard to the potential prognostic significance of noncanonical Wnt signaling in prostate cancer. They focus on clinical evidence for noncanonical Wnt pathway components to serve as potential prognostic biomarkers. [Expert Rev Mol Diagn] Abstract Visit our reviews page to see a complete list of reviews in the prostate cell research field. | |
| |
INDUSTRY NEWSThe Janssen Pharmaceutical Companies of Johnson & Johnson announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a Positive Opinion recommending approval for expanding the use of Erleada® to include the treatment of adult men with metastatic hormone-sensitive prostate cancer in combination with androgen deprivation therapy. [Janssen Pharmaceutica (BusinessWire, Inc.)] Press Release iTeos Therapeutics SA announced that it has entered into an agreement with a subsidiary of Merck to evaluate the safety and efficacy of EOS100850, iTeos’ investigational A2A receptor antagonist, in combination with KEYTRUDA®, Merck’s anti-PD-1 therapy, in patients with solid tumors. [iTeos Therapeutics SA] Press Release Positive DARRT-1 Data in Late-Stage Prostate Cancer Noxopharm reports positive end-of-study data from its DARRT-1 Phase Ib trial. The context here is that men in DARRT-1 had late-stage, progressive disease and had exhausted all available treatment options. [Noxopharm (GlobeNewswire, Inc.)] Press Release | |
| |
POLICY NEWSUK Election Dashes Scientists’ Hopes of Staying in the EU The United Kingdom is now firmly on the path towards leaving the European Union, after the Conservative party won a majority of 79 seats in yesterday’s general election – a result that has major implications for science. [Nature News] Editorial United States Drops Charges against Two More Scientists after Iran Prisoner Swap US authorities have dropped charges against two researchers accused of attempting to export chemicals to Iran in violation of trade sanctions. The decision follows a prisoner swap in which the United States freed a third researcher who was charged alongside them – and imprisoned. [Nature News] Editorial KU Leuven Investigates Whether Stem Cell Scientist Falsified Data KU Leuven is investigating allegations that one of its researchers, acclaimed stem cell biologist Catherine Verfaillie, was involved in falsifying research in at least 10 scientific papers published between 1999 and 2018, Belgian newspaper De Tijd reported last week. [The Scientist] Editorial
| |
EVENTSNEW Beyond a Million Genomes: From Discovery to Precision Health Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Endowed Chair Faculty – Genitourinary Malignancies Research Center (Cleveland Clinic) Postdoctoral Fellowship – Mechanisms of Androgen and Glucocorticoid Metabolism (Cleveland Clinic) Postdoctoral Associate – Tumor Metastasis (UPMC Hillman Cancer Center) Postdoctoral Positions – Cancer Research (Max Delbrück Center for Molecular Medicine) Tenure-Track Faculty Scientist Position – Radiation Oncology (New York University) Postdoctoral Studentship – Genomics of Hereditary Prostate Cancer (University of Manchester) Postdoctoral Researcher – Prostate Cancer (University of California, San Francisco) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Prostate Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|